Tabuk Pharma and Hanmi Pharmaceutical have signed an exclusive license and supply agreement for Rolontis® (Eflapegrastim), an innovative biologic for the treatment of chemotherapy-induced neutropenia, across Saudi Arabia and the MENA region. This strategic collaboration underscores Tabuk Pharma’s commitment to expanding…
